Mikhail Blagosklonny is a renowned scientist. He is known for his research that focuses on aging and cancer. Presently, Mikhail works at the New York based Roswell Cancer Institute, which is one of the leading cancer treatment and research institutions. The professor of oncology was born in Russia. He was admitted to the First Pavlov State Medical College in St. Petersburg to study medicine. Blagosklonny graduated with an M.D. in internal medicine before earning a Ph.D. in cardiology and experimental medicine.
In 2002, Mikhail started working for the New York Medical College. He started as an associate professor. Later, Mikhail became a senior scientist at Ordway Research Institute. During his tenure at Ordway, Mikhail Blagosklonny was the head of the organization’s research strategies. He served the institution until 2009. Subsequently, he joined the Roswell Park Cancer Institute. Mikhail Blagosklonny has researched widely on cellular and molecular biology. In addition, he is among the founders of Cell Cycle, which is a journal that covers mitosis and cancer cell recycling.
Moreover, Blagosklonny’s research specializes on cancer therapies that seek to protect human cells from destruction. Over the years, the professor has been researching on bio-gerontology. This field focuses on the study of aging among humans. He has always zeroed in on developing effective anti-aging drugs. In his research, Blagosklonny’s hypothesis looked on how TOR signaling can be used, especially in cancer and aging. He also noted that rapamycin, a cancer drug, could be used to advance the life span of cancer patients. Besides inhibiting the spread of cancer cells, rapamycin can also enhance the immune system of cancer patients. Mikhail posits that he is passionate about seeing a disease-free community. This way, he works towards developing effective cancer and anti-aging drugs. Read more on Impact Journals.
As an editor, Blagosklonny has been working for different journals, including Aging, Oncotarget, and Cell Cycle. Oncotarget focuses on oncology topics. Impact Journals often publishes the open access journal. In addition, Mikhail serves as an associate editor for Cancer Biology and Therapy, International Journal of Cancer, PLOS ONE, and American Journal of Pathology. He is also part of the editorial board that works for Cell Death & Differentiation. View Mikhail’s profile on Loop